Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Recurrent Glioblastoma
NCT05326464Phase 3Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib oral solution in glioblastoma (GBM), sponsored by UT Southwestern Medical Center. Started Oct 2022; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05326464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326464.